[Roxatidine acetate in therapy of reflux esophagitis].

A total of 3409 patients with gastro-oesophageal reflux disease were treated with roxatidine acetate. 60.7% of the patients received a daily dose of 2 x 75 mg roxatidine acetate, and the median duration of treatment was 5 weeks.

[Early evening and late evening administration of roxatidine acetate in therapy of duodenal ulcer].

In a multicenter, placebo-controlled, comparative trial with 196 general practitioners and internists 730 18 to 70 year-old patients with endoscopic evidence of a duodenal ulcer were enrolled. Each group of 365 patients received 150 mg Roxatidine acetate once daily, either late in the evening (bedtime administration, between 10.00 p.

[Therapy of orthostatic disorders of cardiovascular regulation. Placebo controlled double-blind study with oxilofrine].

In a double-blind study, the antihypotensive agent oxilofrine was compared with placebo in patients suffering from orthostatic circulatory regulation disorders of the sympathicotonic type. After a washout period of one week, 30 patients were treated for two weeks with oxilofrine and 30 with placebo. The area of the blood pressure amplitude determined with the Schellong test between the 8th minute prone and the 15th minute erect, increased during treatment with oxilofrine from 126 +/- 21 mmHg x min.